Foghorn Halts FHD-909, Cuts 40% of Staff, Extends Runway to 2029
FHTX is trading near its 52-week low of $3.27 (9.2% above the low).
Summary
Foghorn is discontinuing its FHD-909 program with Lilly and stopping all work on the selective SMARCA2 degrader, effectively ending the collaboration. The company is cutting approximately 40% of its workforce to reduce burn and refocusing on proprietary programs including EP300, CBP, and I&I, and expects to have about 65 full-time employees after the reduction. Management now expects cash runway into the second half of 2029, up from mid-2027, which reduces near-term financing risk. This is a major strategic reset following disappointing clinical data in the partnered oncology program. The refocused pipeline will need clinical entries or data readouts to restore investor confidence.
At the time of this announcement, FHTX was trading at $3.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212M. The 52-week trading range was $3.27 to $7.61. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.